WATCH: Foreign-made drugs could soon face 100% US import tariffs, but that figure is likely an opening bid in negotiations — and there are still compelling ways to invest in healthcare, Impax Asset Management's Nathan Moser says

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.